An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer
{{output}}
The opioid receptor (OR) antagonist naltrexone inhibits estrogen receptor-α (ER) function in model systems. The goal of this study was to determine the clinical activity of naltrexone in patients with ER-positive metastatic breast cancer. Patients with hormon... ...
